Reasons for discontinuation of subcutaneous interferon β-1a three times a week among patients with multiple sclerosis: a real-world cohort study

[1] Wingerchuk DM(2014)Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies Mayo Clin Proc 89 225-240

[2] Carter JL(2015)Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15 J Neurol Neurosurg Psychiatry 86 1202-1207

[3] Kappos L(2010)Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study Clin Drug Investig 30 89-100

[4] Kuhle J(2010)Clinical and economic impact of a specialty care management program among patients with multiple sclerosis: a cohort study Mult Scler 16 956-963

[5] Multanen J(2009)Factors that influence adherence with disease-modifying therapy in MS J Neurol 256 568-576

[6] Kremenchutzky M(2015)Postmarketing safety profile of subcutaneous interferon beta-1a given 3 times weekly: a retrospective administrative claims analysis J Manag Care Spec Pharm 21 650-660

[7] Verdun di Cantogno E(2015)Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study PLoS One 10 e0123824-462

[8] Cornelisse P(2009)Improving compliance with interferon-beta therapy in patients with multiple sclerosis CNS Drugs 23 453-9

[9] Lehr L(2010)Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence Patient Prefer Adherence 4 1-476

[10] Casset-Semanaz F(2002)Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population J Manag Care Pharm 8 469-625

[1] Wingerchuk DM(2014)Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies Mayo Clin Proc 89 225-240

[2] Carter JL(2015)Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15 J Neurol Neurosurg Psychiatry 86 1202-1207

[3] Kappos L(2010)Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study Clin Drug Investig 30 89-100

[4] Kuhle J(2010)Clinical and economic impact of a specialty care management program among patients with multiple sclerosis: a cohort study Mult Scler 16 956-963

[5] Multanen J(2009)Factors that influence adherence with disease-modifying therapy in MS J Neurol 256 568-576

[6] Kremenchutzky M(2015)Postmarketing safety profile of subcutaneous interferon beta-1a given 3 times weekly: a retrospective administrative claims analysis J Manag Care Spec Pharm 21 650-660

[7] Verdun di Cantogno E(2015)Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study PLoS One 10 e0123824-462

[8] Cornelisse P(2009)Improving compliance with interferon-beta therapy in patients with multiple sclerosis CNS Drugs 23 453-9

[9] Lehr L(2010)Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence Patient Prefer Adherence 4 1-476

[10] Casset-Semanaz F(2002)Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population J Manag Care Pharm 8 469-625